Skip to content
Screener

Total Liabilities at other companies

Pfizer logo
PfizerPFE
$3.41B-97.1%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$25.32M+95.4%
CG Oncology logo
CG OncologyCGON
$56.54M+81.9%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$50.17M+91.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$48.4M-14.8%
NTH
Neonc Technologies HoldingsNTHI
$23.76M+60.5%

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$1.34B+59.2%
Enterprise value$1.29B+67.3%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204047
Line itemMarch 31, 2026December 31, 2025
Accrued liabilities14,87616,593
Total current liabilities17,77120,417
Other long-term liabilities3,4344,111
Total liabilities21,20524,528
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 103,486,412 and 98,528,949 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively1111

Item 1. Financial Statements.

FAQ

What is Oric Pharmaceuticals, Inc.'s total liabilities?
Oric Pharmaceuticals, Inc. (ORIC) reported total liabilities of $21.21M in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s total liabilities changed year-over-year?
Oric Pharmaceuticals, Inc.'s total liabilities decreased by 8.3% year-over-year, from $23.12M to $21.21M.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Oric Pharmaceuticals, Inc.'s total liabilities has grown at a 21.6% compound annual growth rate (CAGR), from $9.22M to $24.53M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Oric Pharmaceuticals, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude